19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
13
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Sichuan University
34
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
University of Oxford
56
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
The Institute of Cancer Research
17
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Kyoto Prefectural University of Medicine
4
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.
GlaxoSmithKline R&D
8
Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity.
Osaka University
17
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.
University of Oxford
7
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Kyoto Prefectural University of Medicine
34
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Institute of Cancer Research
38
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
University of Oxford
9
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Sapienza University of Rome
35
Structure-based design and discovery of potent and selective KDM5 inhibitors.
Celgene
7
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Celgene Quanticel Research
